Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moritz Spangemacher

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Therapeutic Drug Monitoring|November 29, 2023
Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic Critical Review on Therapeutic Plasma Concentrations of AntipsychoticsXenia M Hart, Moritz Spangemacher, Hiroyuki Uchida, et al.
Der Nervenarzt|February 24, 2025
[Can antidepressants negatively alter the long-term course of depressive disorders?]Gerhard Gründer, Lea J Mertens, Moritz Spangemacher, et al.
Therapeutic Drug Monitoring|January 30, 2024
Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of AntidepressantsXenia M Hart, Moritz Spangemacher, Julie Defert, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 3, 2025
Psychedelics: The pathway to implementation in the European healthcare systemsGerhard Gründer, Lea J Mertens, Moritz Spangemacher, et al.
Deutsches Arzteblatt International|December 4, 2024
Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in PsychiatryMoritz Spangemacher, Lea J Mertens, Luca V Färber, et al.
Der Nervenarzt|February 1, 2022
[Are psychedelics fast acting antidepressant agents?]Gerhard Gründer, Manuela Brand, Laura Kärtner, et al.
Der Nervenarzt|January 17, 2025
[Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment]Moritz Spangemacher, Jonathan Reinwald, Hana Adolphi, et al.
Translational Psychiatry|October 1, 2025
The sense and nonsense of antipsychotic combinations: A model for dopamine D<sub>2/3</sub> receptor occupancyMoritz Spangemacher, Christian N Schmitz, Paul Cumming, et al.
Annals of General Psychiatry|August 27, 2024
Association between rTMS-induced changes in inflammatory markers and improvement in psychiatric diseases: a systematic reviewBruno Pedraz-Petrozzi, Shrabon Insan, Moritz Spangemacher, et al.
The Lancet. Psychiatry|December 15, 2023
Treatment with psychedelics is psychotherapy: beyond reductionismGerhard Gründer, Manuela Brand, Lea J Mertens, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Therapeutic Drug Monitoring|November 29, 2023
Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic Critical Review on Therapeutic Plasma Concentrations of AntipsychoticsXenia M Hart, Moritz Spangemacher, Hiroyuki Uchida, et al.
Der Nervenarzt|February 24, 2025
[Can antidepressants negatively alter the long-term course of depressive disorders?]Gerhard Gründer, Lea J Mertens, Moritz Spangemacher, et al.
Therapeutic Drug Monitoring|January 30, 2024
Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of AntidepressantsXenia M Hart, Moritz Spangemacher, Julie Defert, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|December 3, 2025
Psychedelics: The pathway to implementation in the European healthcare systemsGerhard Gründer, Lea J Mertens, Moritz Spangemacher, et al.
Deutsches Arzteblatt International|December 4, 2024
Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in PsychiatryMoritz Spangemacher, Lea J Mertens, Luca V Färber, et al.
Der Nervenarzt|February 1, 2022
[Are psychedelics fast acting antidepressant agents?]Gerhard Gründer, Manuela Brand, Laura Kärtner, et al.
Der Nervenarzt|January 17, 2025
[Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment]Moritz Spangemacher, Jonathan Reinwald, Hana Adolphi, et al.
Translational Psychiatry|October 1, 2025
The sense and nonsense of antipsychotic combinations: A model for dopamine D<sub>2/3</sub> receptor occupancyMoritz Spangemacher, Christian N Schmitz, Paul Cumming, et al.
Annals of General Psychiatry|August 27, 2024
Association between rTMS-induced changes in inflammatory markers and improvement in psychiatric diseases: a systematic reviewBruno Pedraz-Petrozzi, Shrabon Insan, Moritz Spangemacher, et al.
The Lancet. Psychiatry|December 15, 2023
Treatment with psychedelics is psychotherapy: beyond reductionismGerhard Gründer, Manuela Brand, Lea J Mertens, et al.
Pageof 2